Search
Galmed Pharmaceuticals Ltd
GLMDAdd to Watchlist
0.563USD
+0.040+7.55%
Market hours （ET）Quotes delayed by 15 min
3.71MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Galmed Pharmaceuticals Ltd is 6.00, ranking 329 out of 387 in the Biotechnology & Medical Research industry.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Galmed Pharmaceuticals Ltd
GLMD
1
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
How have Galmed Pharmaceuticals LtdGLMD's recent earnings per share performed?
The market expectation was USD -0.29, while Galmed Pharmaceuticals LtdGLMD's earnings per share (EPS) for the previous quarter was USD -0.80. EPS for the next quarter is expected at USD -0.39.
What is the analyst rating for Galmed Pharmaceuticals Ltd?
Based on the ratings of Galmed Pharmaceuticals Ltd's stock from 1 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.